Immunoadsorption as a method of antibody donation during the COVID‐19 pandemic
Vox Sanguinis · 2024
DOI: 10.1111/vox.13647 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vox Sanguinis, 2024. Verfasst von Jannik Rothenburg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Transplant Diagnostics and Cell Therapeutics, University Hospital Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Antibodies, Viral, Antibodies, Neutralizing. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objectives Initial therapeutic efforts to treat severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) included the use of plasma from convalescent donors containing anti‐SARS‐CoV‐2 antibodies. High‐neutralizing antibody titres are required for therapeutic efficacy. This study aims to show that immunoadsorption followed by tangential flow filtration can be used to obtain antibody concentrates with high‐neutralizing capacities. Materials and Methods Eligible donors ( n = 10, five males and three females) underwent immunoadsorption using adsorber columns specific for human antibodies. Glycine‐washed out eluates of 1.5 L volume were further concentrated by tangential flow filtration using 30 kDa ultrafiltration membranes. The same membranes were applied for diafiltrations to exchange residual glycine for 0.9% normal saline.
Results
Antibody concentrates were obtained within 8 h from the start of donation and had 4.58 ± 1.95, 3.28 ± 1.28 and 2.02 ± 0.92 times higher total IgG, IgA and IgM concentrations, 3.29 ± 1.62 and 3.74 ± 0.6 times higher SARS‐CoV‐2 N and S antibody concentrations and 3.85 ± 1.71 times higher SARS‐CoV‐2 S‐specific IgG concentrations compared to the donors' peripheral blood. The specific SARS‐CoV‐2 virus neutralization capacities increased in all but one concentrate. All antibody concentrates (50–70 mL final volume) passed microbiological tests, were free of hazardous glycine levels and could be stored at −80°C and 4°C for 1 year with 20 ± 3% antibody loss.
Conclusion
Immunoadsorption followed by tangential flow filtration is a feasible procedure to collect IgG, IgA and IgM as well as SARS‐CoV‐2 N‐ and S‐specific antibody concentrates of low volume, free of albumin and coagulation factors. Whether these concentrates can be used as passive immunisation in infected patients remains to be elucidated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Transplant Diagnostics and Cell Therapeutics, University Hospital Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany.
- Cytiva, Dreieich, Germany.
- Miltenyi Biotec, Bergisch Gladbach, Germany.
- Institute of Virology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany.
- Central Institute of Laboratory Medicine, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany.
- Department of Nephrology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany.
ORCID-Profile: Jannik Rothenburg, Anja Moldenhauer
Zitieren
APA
Rothenburg, J., Rink-Baron, S., Müller, L., Ostermann, P. N., Fischer, J. C., Hermsen, D., Stegbauer, J., & Moldenhauer, A. (2024). Immunoadsorption as a method of antibody donation during the COVID‐19 pandemic. Vox Sanguinis. https://doi.org/10.1111/vox.13647
Vancouver
Rothenburg J, Rink-Baron S, Müller L, Ostermann PN, Fischer JC, Hermsen D, et al. Immunoadsorption as a method of antibody donation during the COVID‐19 pandemic. Vox Sanguinis. 2024. doi:10.1111/vox.13647
BibTeX
@article{Rothenburg2024,
author = {Rothenburg, Jannik and Rink-Baron, Silke and Müller, Lisa and Ostermann, Philipp Niklas and Fischer, Johannes C and Hermsen, Derik and Stegbauer, Johannes and Moldenhauer, Anja},
title = {Immunoadsorption as a method of antibody donation during the COVID‐19 pandemic},
journal = {Vox Sanguinis},
year = {2024},
doi = {10.1111/vox.13647}
}
EUVIMED